Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study

January 11, 2016 12:38 PM

16 0

Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study.

The drug, CHS-0214, was found to be as effective as Enbrel in rheumatoid arthritis patients, with no clinically meaningful differences in terms of its safety, the companies said on Monday.

Also read: Attorney General's office announces settlement with drug manufacturer

Read more

To category page

Loading...